Simplex Trading’s Cytek Biosciences CTKB Stock Holding History

Simplex Trading’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24K	Hold	5,500	–	–	﹤0.01%	6616
2025 Q4	$27.8K	Buy	5,500 +4,700	+588%	+$21.8K	﹤0.01%	6176
2025 Q3	$2K	Hold	800	–	–	﹤0.01%	8620
2025 Q2	$2K	Buy	800 +300	+60%	+$1K	﹤0.01%	8104
2025 Q1	$2K	Buy	+500	New	+$2.59K	﹤0.01%	7954
2024 Q4	–	Sell	-1,000	Closed	-$5K	–	8668
2024 Q3	$5K	Hold	1,000	–	–	﹤0.01%	7591
2024 Q2	$5K	Buy	+1,000	New	+$6.01K	﹤0.01%	7844
2023 Q4	–	Sell	-500	Closed	-$2K	–	8930
2023 Q3	$2K	Hold	500	–	–	﹤0.01%	8059
2023 Q2	$4K	Buy	+500	New	+$4.49K	﹤0.01%	8013
2023 Q1	–	Sell	-200	Closed	-$2K	–	9176
2022 Q4	$2K	Buy	+200	New	+$2.69K	﹤0.01%	8544

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Simplex Trading's CTKB Position: Q1 2026 in Review

Simplex Trading increased its Cytek Biosciences (CTKB) stake by 61% in Q1 2026, buying an estimated $5.77K and bringing the position to 3,226 shares worth $14.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7046.

Simplex Trading first reported a position in CTKB in Q4 2023 and has held it in 9 quarters since. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

Simplex Trading held 3,226 shares of Cytek Biosciences worth $14.1K as of Q1 2026.
Simplex Trading bought 1,223 Cytek Biosciences shares in Q1 2026, an estimated $5.77K.
Cytek Biosciences made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #7046 holding.
Simplex Trading first reported a position in Cytek Biosciences in Q4 2023 and has held it in 9 quarters since.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.